Anticoagulation in pulmonary arterial hypertension

Jeffrey C. Robinson, Steven C. Pugliese, Daniel L. Fox, David B. Badesch

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Pulmonary arterial hypertension (PAH) is characterized by molecular and pathologic alteration to the pulmonary circulation, resulting in increased pulmonary vascular resistance, right ventricular failure, and eventual death. Pharmacologic treatment of PAH consists of use of a multitude of pulmonary vasodilators, sometimes in combination. PAH has been associated with increased thrombosis and disrupted coagulation and fibrinolysis, making anticoagulation an attractive and frequently employed therapeutic modality. Observational studies have provided some insight into the therapeutic potential of anticoagulation in idiopathic PAH, but there is a distinct lack of wellcontrolled prospective trials. Due to the conflicting evidence, there is a large amount of heterogeneity in the application of therapeutic anticoagulation in PAH and further well-controlled prospective trials are needed to clarify its role in treating PAH.

Original languageEnglish (US)
Article number47
JournalCurrent Hypertension Reports
Volume18
Issue number6
DOIs
StatePublished - Jun 2016
Externally publishedYes

Keywords

  • Anticoagulation
  • Pulmonary hypertension
  • VitaminK antagonists
  • Warfarin

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Anticoagulation in pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this